PeptideStack
5.2kquestions
20kanswers
220users

What happens to retatrutide after two weeks at 4 °C in solution?

Asked 16 Sept 2024Modified 19 months agoViewed 37k times
20

Setup, so nobody has to ask: retatrutide · two weeks · 4 °C.

The empirical answer seems settled. The explanation does not.

If the honest answer is that nobody knows, I would rather hear that than a plausible story.

What is the causal chain, and where does it stop being established?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
shareeditfollowflag
EH
askedeighty_six_hours20k2716 Sept 2024

5 Answers

Accepted answer first, then by votes
86

Accepted answer

two weeks is 14 days, which at 4 °C is on the order of 13 refrigerated days. 4 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. In solution the routes that matter are hydrolysis of the backbone, deamidation at Asn, and physical association — the first two cost content, the third costs neither until it precipitates. Over 14 days at 4 °C you should expect all three to have moved, and a purity figure to have noticed only some of them. Reconstituted material has no certificate; the one in the box describes the powder.

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

At dilute concentrations, suspect adsorption before you suspect chemistry.

edited 15 Oct 2024 by harriet_lonsdale — updated for the 2026 guidance change

shareimprove this answerflag
HL
answered · acceptedharriet_lonsdale35k1383 Oct 2024
Is there a reason to prefer minus eighty here, or is minus twenty genuinely enough? – marta_okonkwo 7 months ago
2Same experience here, different supplier. – tenth_of_a_unit 8 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
32

Asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

On the detail: light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Sequence decides which pathways are even available. Check the residues.

shareimprove this answerflag
SF
answeredshear_at_the_front17k2714 Oct 2024
27

Start with the sequence, because which pathways are available depends on which residues are present.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
LC
answeredlyoph_cake78k26725 Oct 2024
21

Concretely, this is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

Cold, dry, dark, still. Those four words cover most of the mitigation.

shareimprove this answerflag
OB
answeredone_ml_bac18k275 Nov 2024
5Does the same reasoning apply to material already in solution, or is that a different curve? – Dr_Colm_Fitzhenry 9 months ago
add a comment
19

Stated carefully, aggregation is a physical process and is the one most often caused by handling rather than by time.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

shareimprove this answerflag
TQ
answeredtriple_agonist_q57k3817 Dec 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.